Recombinant Factor VIIa Does not Induce Hypercoagulability In Vitro

Siegfried Gallistl; Gerhard Cvirn; Wolfgang Muntean

doi:10.1055/s-0037-1614451

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1999; 81(02): 245-249
DOI: 10.1055/s-0037-1614451

Review Articles

Schattauer GmbH

Recombinant Factor VIIa Does not Induce Hypercoagulability In Vitro

Siegfried Gallistl

¹From the Dept of Paediatrics, Ludwig Boltzmann Research Institute for Paediatric Haemostasis and Thrombosis, University of Graz, Austria

,

Gerhard Cvirn

¹From the Dept of Paediatrics, Ludwig Boltzmann Research Institute for Paediatric Haemostasis and Thrombosis, University of Graz, Austria

,

Wolfgang Muntean

¹From the Dept of Paediatrics, Ludwig Boltzmann Research Institute for Paediatric Haemostasis and Thrombosis, University of Graz, Austria

› Author Affiliations

Abstract

Summary

Recombinant factor VIIa (rVIIa) has been reported to be clinically effective and safe in haemophilic patients with inhibitor antibodies. Compared to activated prothrombin complex concentrates the risk of thrombotic complications seems to be very low after rVIIa administration. Determination of free thrombin generation has been shown to identify hypercoagulability. Therefore, free thrombin and prothrombinase activity (Xa generation) were assessed after extrinsic activation of rVIIa supplemented factor VIII and factor IX deficient plasma. Free thrombin generation was also determined after supplementation of (activated) prothrombin complex concentrates. Addition of 150 U rVIIa/ml shortened the clotting times markedly in control, factor VIII, and factor IX deficient plasma. In contrast, free thrombin and Xa generation were not different in the absence or presence of 150 U rVIIa/ml. Addition of (activated) prothrombin complex concentrates resulted in a marked increase of free thrombin generation in all investigated plasmas. Although in vitro studies cannot reflect specific clinical circumstances our results support the notion that rVIIa does not induce a hypercoagulable state as sporadically observed after administration of (activated) prothrombin complex concentrates.

Full Text

References

References
1 Hedner U, Glazer S, Falch J. Recombinant activated factor VII in the treatment of bleeding episodes in patients with inherited and acquired bleeding disorders. Transfus Med Rev 1993; 7: 78-83.
2 Hedner U, Bjoern S, Bernvil SS, Tengborn L, Stigendahl L. Clinical experience with human plasma-derived factor VIIa in patients with hemophilia A and high titer inhibitors. Haemostasis 1989; 19: 335-43.
3 Hay CRM, Negrier C, Ludlam CA. The treatment of bleeding in acquired haemophilia with recombinant factor VIIa: A multicentre study. Thromb Haemost 1997; 78: 1463-7.
4 Bauer KA. Treatment of factor VII deficiency with recombinant factor VIIa. Haemostasis 1996; 26 (Suppl. 01) Suppl 155-8.
5 Bernstein DE, Jeffers L, Erhardtsen E, Reddy KR, Glazer S, Squiban P, Bech R, Hedner U, Schiff ER. Recombinant factor VIIa corrects prothrombin time in cirrhotic patients: a preliminary study. Gastroenterology 1997; 113: 1930-7.
6 Kristensen J, Killander A, Hippe E, Helleberg C, Ellegard J, Holm M, Kutti J, Mellqvist UH, Johansson JE, Glazer S, Hedner U. Clinical experience with recombinant factor VIIa in patients with thrombocytopenia. Haemostasis 1996; 26 (Suppl. 01) Suppl 159-64.
7 Lusher JM. Use of prothrombin complex concentrates in the management of bleeding in hemophiliacs with inhibitorS-benefits and limitations. Semin Haematol 1994; 31: 49-52.
8 Chistolini A, Mazzucconi MG, Tirindelli MC, La Verde G, Ferrari A, Mandelli F. Disseminated intravascular coagulation and myocardial infarction in a haemophilia B patient during therapy with prothrombin complex concentrates. Acta Haematologica 1990; 83: 163-5.
9 Chavin I S, Siegel DM, Rocco TA, Olsen JF. Acute myocardial infarction during traetment with an activated prothrombin complex concentrate in a patient with factor VIII deficiency and a factor VIII inhibitor. Am J Med 1988; 85: 244-9.
10 Bauer KA. Activation of the factor VII-tissue factor pathway. Thromb Haemost 1997; 78: 108-11.
11 Rapaport I S, Rao LV. The tissue factor pathway: how it has become a “pri-ma ballerina”. Thromb Haemost 1995; 74: 7-17.
12 Sandset PM. Tissue factor pathway inhibitor (TFPI)- an update. Haemostasis 1996; 26 (Suppl. 04) Suppl 154-65.
13 ten Cate H, Bauer KA, Levi M, Edgington TS, Sublett RD, Barzegar S, Kass BL, Rosenberg RD. The activation of factor X and prothrombin by recombinant factor VIIa in vivo is mediated by tissue factor. J Clin Invest 1993; 92: 1207-12.
14 Hemker HC, Beguin S. Thrombin generation in plasma: its assessment via the endogenous thrombin potential. Thromb Haemost 1995; 74: 134-8.
15 Hemker HC, Wielders S, Kessels H, Beguin S. Continuous registration of thrombin generation in plasma, its use for the determination of the thrombin potential. Thromb Haemost 1993; 70: 617-24.
16 Wielders S, Mukherjee M, Michiels J, Rijkers DT, Cambus JP, Knebel RW, Kakkar V, Hemker HC, Beguin S. The routine determination of the endogenous thrombin potential, first results in different forms of hyper- and hypocoagulability. Thromb Haemost 1997; 77: 629-36.
17 Gallistl S, Muntean W. Thrombin-hirudin complex formation, thrombinantithrombin III complex formation, and thrombin generation after intrinsic activation of plasma. Thromb Haemost 1994; 72: 387-392.
18 Gallistl S, Muntean W, Leis HJ. Effects of heparin and hirudin on thrombin generation and platelet aggregation after intrinsic activation of platelet rich plasma. Thromb Haemost 1995; 74: 1163-8.
19 Gallistl S, Muntean W, Zenz W. Gly-Pro-Arg-Pro (GPRP) enhances the generation of thrombin. Thromb Res 1995; 78: 547-550.
20 Beguin S, Lindhout T, Hemker HC. The mode of action of heparin in plasma. Thromb Haemost 1988; 60: 457-62.
21 Telgt DS, Macik BG, McCord DM, Monroe DM, Roberts HR. Mechanism by which recombinant factor VIIa shortens the aPTT: activation of factor X in the absence of tissue factor. Thromb Res 1989; 56: 603-9.
22 Macik BG, Lindley CM, Lusher J, Sawyer WT, Bloom AL, Harrison JF, Baird-Cox K, Birch K, Glazer S, Roberts HR. Safety and initial clinical efficacy of three dose levels of recombinant activated factor VII (rFVIIa): results of a phase I study. Blood Coagul Fibrinolysis 1993; 4: 521-7.
23 Diness V, Bregengaard C, Erhardtsen E, Hedner U. Recombinant human factor VIIa (rFVIIa) in a rabbit stasis model. Thromb Res 1992; 67: 233-41.
24 Monroe DM, Hoffman M, Oliver JA, Roberts HR. Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol 1997; 99: 542-7.
25 Rapaport I S, Rao LVM. Initiation and regulation of tissue factor-dependent blood coagulation. Arterioscler Thromb 1992; 12: 1111-21.
26 Mannucci PM, Bauer KA, Gringeri A, Barzegar S, Santagostino E, Tradati FC, Rosenberg RD. No activation of the common pathway of the coagulation cascade after a highly purified factor IX concentrate. Br J Haematol 1991; 79: 606-11.
27 Giles AR, Nesheim ME, Hoogendoorn H, Tracy PB, Mann KG. The coagulant-active phospholipid content is a major determinant of in vivo thrombogenicity of prothrombin complex (Factor IX) concentrates in rabbits. Blood 1982; 59: 401-7.
28 Magner A, Aronson D. Toxicity of factor IX concentrates in mice. Dev Biol StandM 1979; 44: 185-8.
29 Andrew M, Schmidt B, Mitchell L, Paes B, Ofoso F. Thrombin generation in newborn plasma is critically dependent on the concentration of prothrombin. Thromb Haemost 1990; 63: 27-30.